NCT06260683 A Comprehensive Evaluation of Tobacco-Flavored vs. Non-Tobacco Flavored E-cigarettes on Smoking Behavior
| NCT ID | NCT06260683 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ohio State University Comprehensive Cancer Center |
| Condition | Cigarette Smoking-Related Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2024-04-10 |
| Primary Completion | 2028-04-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,500 participants in total. It began in 2024-04-10 with a primary completion date of 2028-04-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial compares the use of tobacco flavored electronic cigarettes (ECs) vs. non-tobacco flavored ECs vs. nicotine replacement therapy (patches and lozenges) on smoking behavior in current cigarette smokers. ECs may reduce cigarette craving and withdrawal symptoms, increase motivation and confidence to stop cigarette smoking, and decrease cigarette smoking and dependence. By comparing participants' preferred flavor ECs (PEC) to tobacco flavor ECs (TEC) to NRT, researchers hope to determine the effect of EC flavors on appeal and use and learn how ECs affect smoking behaviors and health.
Eligibility Criteria
Inclusion Criteria: * \>= 21 years old * Smoke \>= 5 cigarettes per day for the past year * Willing to use either an EC or NRT * Read and speak English * Have a smartphone Exclusion Criteria: * Report currently using smoking cessation medications, NRT, or actively seeking treatment for smoking cessation * Current use of an EC \> 4 days a month * Diagnosed medical conditions of lung disease, asthma, cystic fibrosis, heart disease or chronic obstructive pulmonary disease (COPD) * Unmanaged (unmedicated and/or without counseling) diagnosis of schizophrenia * History of cardiac event or distress within the past 3 months * Currently pregnant, planning to become pregnant within 6 months, or breastfeeding * High blood pressure not controlled by medications * Serious angina pectoris or chest pain * Stroke within the past three months * Known allergy to propylene glycol or vegetable glycerin * Serious underlying arrhythmias, irregular heartbeat or abnormal heart rhythm * Live in same household as another study participant
Contact & Investigator
Theodore L Wagener, PhD
PRINCIPAL INVESTIGATOR
Ohio State University Comprehensive Cancer Center
Frequently Asked Questions
Who can join the NCT06260683 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, studying Cigarette Smoking-Related Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06260683 currently recruiting?
Yes, NCT06260683 is actively recruiting participants. Contact the research team at OSUCCCClinicaltrials@osumc.edu for enrollment information.
Where is the NCT06260683 trial being conducted?
This trial is being conducted at Columbus, United States.
Who is sponsoring the NCT06260683 clinical trial?
NCT06260683 is sponsored by Ohio State University Comprehensive Cancer Center. The principal investigator is Theodore L Wagener, PhD at Ohio State University Comprehensive Cancer Center. The trial plans to enroll 1,500 participants.